Everything in the world !

pharma stocks analysis for pharma stocks the fall may not be done yet - Search

The pharma stocks analysis for pharma stocks the fall may not be done yet searched through all the site information that is gathered from around the web. To view the complete news story please click on the title link.

pharma stocks: analysis: for pharma stocks, the fall may not be done yet

while the erosion in drug prices in the us is not a sudden phenomenon, it is the latest development to have hit the prospects of generic pharma companies globally. it poses a more serious challenge than the us food and drug administration regulatory issue since it is universal in its impact and has been intensifying in the past few quarters. issues taken up by the usfda are plant-specific, of differing gravity, and allow companies to take remedial measures. what is severely puncturing confidence in the sector is the rapidly changing `new normal' for the pharma companies' woes in the us, their largest and most lucrative market. what was assumed to be an 8-10 per cent of price erosion is now feared to be in the range of 10-15 per cent. globally, pharma companies are giving profit warnings ..

stocks: three pharma stocks you should accumulate now: avinnash gorakssakar

in a chat with et now, avinnash gorakssakar, independent expert, says lupin, aurobindo and sun pharma offer upside breakout opportunity. edited excerpts: give us three names where you think there is potential of an upside breakout fundamentally?apart from sun pharma i would believe that even aurobindo pharma looks interesting. they have got a clean chit for all their plants and other one would be lupin. of course, lupin has an inspection on the 17th of april but my guess is if they do not get any major observations here than lupin is also poised to to do pretty well. in fact, their us as well as their japanese molecule built up is pretty solid. i would believe that lupin, aurobindo pharma and sun pharma could be accumulated. et now: would you like to comment on sun pharma and particular th

stocks: investors in pharma stocks need to temper expectations

et intelligence group: the sustained downtrend in stocks of pharmaceutical companies in recent months shows that no sector is evergreen. once favoured as a defensive pick, pharma stocks have fallen out of favour due to heightened regulatory risk that is real and all-pervasive. the best of the pharma companies have been falling short on compliance with us food and drug administration standards, despite the us being the most critical market for them. the usfda scare is, however, not the only worry for investors. systemic factors such as price erosion and delayed drug approvals amid intense competition have also been impacting the business in the us. besides, the regulatory regime in the domestic market has posed challenges for the companies. price controls, ban on fixed-dose combinations and

pharma stocks: how trump, fda policies may change the way you look at the pharma

new delhi: us president donald trump’s talk of lowering drug pricing by increasing competition in the pharma sector may result in streamlining of the usfda approval process, which may not only reduce development costs, but also increase the pace of fda approvals in the short term. but, it may lead to price erosion in the long run, say brokerages. foreign brokerage bofa-ml in a note said the measures are all set to be beneficial for those indian pharma companies which have large pending pipelines consisting of increasingly complex generic drugs. “the streamlining of the fda approval process and a faster rate of generic drug approvals enjoys bipartisan support in the us legislature. several pending bills are aimed at introducing incentives for pharma companies to develop and obtain appro...

play pharma as a basket, aviation is risky: dipan mehta

in a chat with et now, dipan mehta, member, bse & nse, says the best approach is to buy a basket of pharma shares which have been consistently performing well and which have managed usfda regulation well in the past. edited excerpts: it is aurbindo pharma today, yesterday it was drl, and day before, it was wockhardt. how should one approach the pharma space because it is interesting that wockhardt despite the negative news of a warning letter did not quite fall because it seems like it is one of those cases as to how much more will the stock fall? how are you approaching pharma now?pharma is too large a sector and the dynamics are such that an investor cannot really ignore it and these events do take place and can’t be predicted. for example, i heard aurobindo’s four plants are coming ...

etmarkets after hours: avenue supermarts doubles on listing day; banking, pharma

domestic equity indices extended their fall for the second straight day as lingering concerns over possible usfda crackdown on select pharma firms triggered selling on the healthcare counter while banking stocks took a beating after a downgrade by global investment firm morgan stanley. the 30-share bse sensex closed 33.29 points, or 0.11 per cent, down at 29,485, while the 50-share nse nifty index fell 5.35 points, or 0.06 per cent, to 9,121. here’s a look at the stocks and sectors that hogged limelight on tuesday. d-mart’s dream debut: shares of avenue supermarts on tuesday made a spectacular debut on bse, as its shares got listed at rs 604, a 102.14 per cent premium over its issue price of rs 299 apiece. later, the scrip closed 117.37 per cent higher at rs 649 against the issue price...

sensex: top 10 stocks that can turn out to be potential winners over next five y

new delhi: are you an investor who believes in holding stocks and reaping the harvest of wealth creation? this can happen only if you give time to your investment and remain patient. retail investors who are not able to read the pulse of the market at regular intervals are always in search of stocks that can give higher returns from other asset classes such as real estate, bonds, bank deposits and gold. in its latest strategy report on india, morgan stanley has handpicked 10 stocks that can turn out to be potential winners only if you are willing to give time to your investment. the time horizon the global investment bank has specified for these stocks is five years. stocks that fall in the category of potential winners include asian paints, eicher motors, glenmark pharma, hcl technologies

deven choksey: we have been focusing on mid and smallcap space: deven choksey

in a chat with et now, deven choksey, md, kr choksey investment managers, says 15% growth is definitely possible in many of the frontline pharma companies on a year-on-year basis edited excerpts: why are pharma stocks falling the way they are?it is obviously the usfda issue. most of the pharma companies have corrected their practices and they have become re-compliant. the overhang of the situation continues. on one side, the government is formulating new ways of selling generics in the markets. so branded generics, which have been charging premium, probably would face pressure on the margin as far as the domestic market is concerned. clarity is also required for supply pipeline. pharma companies have got a good anda pipeline visibility and a 15-20% growth is a given, but we are so used to

sensex: where to shop when the street is so high: top stock picks

the bse sensex ended above 30,000 for the first time in its 40-year history with 256 stocks hitting 52-week highs on wednesday and 118 stocks closing at record highs. with sensex trading at 18 times its fy18 estimated earnings and most of the quality stocks trading above their historical valuations, investors are finding it tough to find good stocks to invest. for those who missed this rally here are some stocks they can still bet on. centrumstrides shasun cmp: rs 1,091 | target price: rs 1,317centrum capital is positive on strides due to its transformation into an integrated pharma player post the shasun merger, enhanced focus on regulated markets, re-aligned strategy to become a fully integrated b2c player, strong growth outlook and improvement in margin. byke hospitality cmp: rs 209 | t

we are bullish on 3 pharma stocks: dhananjay sinha, emkay global

in a chat with et now, dhananjay sinha, emkay global, says one has to be very selective in pharma. aurobindo, sun pharma, cipla are his picks in this space. edited excerpts: et now: there are now question marks on whether or not infosys will manage to deliver on the 2020 guidance. the guidance is getting lowered, the numbers are falling short of expectations and there are no details on a buyback, except the fact, that it is going to happen in fy18 but no significant or specific timeline being announced by the management. what has been your own observation on infy and are we likely to see some underperformance in the stock in the days to come? dhananjay sinha: on the back of the fact that there were certain issue with respect to management earlier and there were some controversies around th

etmarkets after hours: psu bank stocks hit, 106 [email protected] high

new delhi: investors continued to play safe in the domestic equity market on tuesday, as equities slipped in every attempt to break out. profit booking on the cement, auto and pharma counters weighed on the benchmark indices. dearth of solid global as well local cues kept the market rangebound, with only a few stocks managing to see some movement. here is a list of sectors and stocks that hogged limelight on tuesday. psu banks continued slide: shares of public sector banks continued to fall on tuesday, as the recent ordinance enabling rbi to crack down on bad loans was expected to hit bank bottomlines. the nifty psu bank index was the biggest sectoral loser on nse, with shares of canara bank falling 5.52 per cent to rs 373.20. union bank plunged 4.64 per cent to rs 178.95, while bank of in

nbfcs: pain in psbs, nbfcs, pharma stocks: mid, smallcaps lose a bit of shine

shares of smalland mid-cap companies, best performers in the past four years, have given up a portion of their gains in recent sessions as investors are cutting positions in richly-valued firms. nearly 70 of the bse 500 stocks have declined between 20% and 70% from their highs in 2017, whereas about 200 stocks corrected between 10% and 20%. analysts said earnings in the fourth quarter have disappointed, prompting investors to sell in this segment. “mid & small-cap stocks have rallied ahead of their fundamentals and now as their results are not justifying their valuations, investors started booking profits," said sanjiv bhasin, executive vp market, iifl. while sensex has declined 1% from its 2017 high, both bse midcap and smallcap indices have dropped nearly 6% from their 2017 highs. the...

come april only corporate earnings will matter: rajat sharma, sana securities

in a chat with et now, rajat sharma, ceo, sana securities, says it is the perfect time to accumulate pharma and it because even if they fall from here, you would not mind holding some of these stocks. edited excerpts: which way do you think we are likely to drift? most of the triggers are behind us. we have come on the right side of the fed, we have come on the right side of the elections. what next?first of all, right now what we have been seeing for the last couple of months is a purely liquidity-based rally. if you look at these markets, fundamentally this is not a great time to invest in stocks. everything looks really really expensive valuation wise. having said that, that is how it has been when nifty was at 8000 levels. today it is at 9000 levels and i would not be surprised if this

stocks: bullish on two stocks in largecap and midcap space for next 9-12 months:

in a chat with et now, pankaj sharma , independent market expert, says his largecap pick is maruti and the midcap pick is torrent power. edited excerpts: is there still any buying opportunity in the market? are there stocks which are in the value zone or would you say the best approach is to just keep on holding what you have been making money on and ride this wave?there is really not much to change the thesis because most of the important sectors -- whether it is bfsi or it or pharma or infrastructure – have not seen much of a change in last three to six months. probably the only thing which we can highlight is somewhere in terms of how the story would pan out for fmcg and auto sectors as we had seen the kind of impact people had feared and expected from demonetisation that has been the..

midcaps’ valuation premium to large stocks scares many; selloff on the cards?

new delhi: indian bank, biocon, bajaj finserv, jspl and l&t finance are some of the midcap stocks, which have rallied up to 180 per cent in last one year largecap bharti airtel might have remained flat in last one year, and peer idea cellular may have risen a mere 6 per cent during the same period, but midcap tata communications has shot up as much as 110 per cent in the comparable period, making investors go crazy. the sbi stock generated 43 per cent return during this period, but it looks meagre compared with the 176 per cent surge in the indian bank stock. sun pharma’s 13 per cent fall and cipla’s 13 per cent rise may have disappointed many, but biocon’s 145 per cent rise surprised all. the valuation premiums that midcap stocks are enjoying over their largecap peers have been wide...

sell aurobindo pharma, target rs 540: kunal bothra

independent analyst kunal bothra has a sell call on aurobindo pharma ltd. with a target price of rs 540.0 .the current market price of aurobindo pharma ltd. is 603.4 time period given by analyst is intra day when aurobindo pharma ltd. price can reach defined target. kunal bothra recommended to keep stop loss at rs 585.0 . aurobindo pharma ltd., incorporated in the year 1986, is a largecap company with a market cap of ₹ 35352.14 crore operating in pharmaceuticals and health care sector. aurobindo pharma ltd. key products/revenue segments include tablets & capsules (formulations) which contributed ₹ 4900.40 cr to sales value (52.56 % of total sales), active pharma ingredients which contributed ₹ 2965.60 cr to sales value (31.81 % of total sales), injections which contributed ₹ 694.65...

sensex news live: 750% return in a decade! d-street’s professor m wields a magic

new delhi: you may not find a wikipedia page on shivanand shankar mankekar, but he is known as ‘professor’ on dalal street. he loves to keep a low profile, but makes big money on his conviction ideas, which often outs him in the limelight. a 100-times return on the pantaloon stock, eye-catching gains on united spirits and a couple of pharma stocks are some of the big stories of this ‘professor’. mankekar, his wife laxmi shivanand mankekar and son kedar mankekar held very few stocks as of december 31, data available on corporate database capitaline showed. but nobody has an idea of his total wealth, as holdings of mankekar and family in most companies have often been less than 1 per cent and, as per the rules, companies disclose names of only those shareholders who hold over 1 per c...

would rather be a contra buyer in it than pharma: abhimanyu sofat, iifl

talking to et now, abhimanyu sofat, iifl, says from a valuation perspective, if you get stocks at multiples of around 9-9.5, then these can be accumulated and made part of the portfolio. edited excerpts: what is the call on some of the consumer names especially itc ahead of numbers?within the consumer bucket, itc looks to be a good stock to bet on considering that it is trading at a discount to its historic valuation, premium to the sensex. the 7.5% price advantage that the cigarette manufacturers are getting because of gst is the icing on the cake. considering where the market is, itc is a good bet at this juncture. investing is all about buying fear. it is all about buying what is cheap. as of now the only two cheap sectors i can see in the market are it and pharma. would you turn a cont

etmarkets after hours: 93 stocks at 52-week low; videocon tumbles more

the domestic equity market settled in the red for the second straight session on wednesday on profit booking over geopolitical tensions and ahead of thursday’s expiry of futures and options contracts. the 30-share bse sensex closed 63.61 points, or 0.21 per cent, down at 30,301, while the nifty50 index of nse settled 25.60 points, or 0.27 per cent, up at 9,360. here’s a look at the stocks and sectors that hogged limelight on wednesday: earnings impact: shares of lupin dipped 1.71 per cent to rs 1,227 on bse on wednesday after the pharma firm posted a 49.16 per cent drop in march quarter net profit at rs 380.21 crore on a 1.33 per cent year-on-year growth in total revenue from operations to rs 4,253.30 crore. another day of big fall: shares of videocon industries were locked in the 10 p...

nifty50: watch out! macd shows 71 stocks may have begun downturn

the nifty50 failed to rise above the 9,500 mark on monday and closed the session with a bearish candle, suggesting that the nifty50 may find it difficult to penetrate the string resistance at 9,490 and 9,520 levels, which may act as the pivotal resistance in the coming sessions. market experts say the downside pivotal support of 9,390 is still intact and the nifty50 may find intermediate support around 9,390. the next downside support is placed around 9,360. the moving average convergence divergence, popularly known as macd, showed as many as 71 stocks on nse witnessed bearish crossovers on monday, signalling a longer bear grip on these counters. stocks that witnessed bearish crossovers with strong volumes on monday included hindalco industries, dlf, maruti suzuki india, aurobindo pharma,

sensex: etmarkets after hours: smallcaps outperform, realty stocks zoom

new delhi: the domestic equity market returned to winning ways on thursday with shares from the recently beaten down sectors such as pharma and realty making decent strides. market sentiment got a boost also from a favourable outcome of the french presidential election. even as the stock market traded rangebound with marginal gains to show, there were plenty of stock-specific action and broader trends that played out through the day. realty stocks gained: the nifty realty index was the biggest sectoral gainer on nse and as real estate stocks continued to rise after the implementation of rera act from may 1. shares of indiabulls real estate zoomed 12.65 per cent to rs 171, housing development and infrastructure gained 7.53 per cent to rs 92.85 and dlf rose 6.65 per cent to rs 198. ipo watch

divi’s lab, ramco, idea among top 25 bse wealth destroyers of fy17

after falling over 9 per cent in the financial year ended march 31, 2015, equity benchmarks sensex and nifty managed to notch up over 15 per cent gains for the financial year (fy16) gone by. but select stocks from the bse500 index rallied up to 288 per cent during the year. at the same time, 82 stocks from this broader market index slipped up to 50 per cent. the top wealth destroyers on the list included intellect systems and ramco systems, which plunged 49 per cent and 46.21 per cent, respectively, between april 1, 2016 and march 31, 2017. among other stocks on the list of wealth destroyers, majesco slipped 41.30 per cent, divi’s lab 37 per cent, inox wind 35 per cent, bajaj hindusthan 33 per cent, mindtree 31 per cent, just dial 30 per cent and gsk pharma 28 per cent. also on the list ..

lupin: sun pharma, torrent, drl & lupin clsa’s top pharma picks

with rapid price deterioration in the simple generics industry in the us, indian pharma companies are in a challenging situation. but at the same time, the importance of india and emerging markets should increase for the drug makers due to the strong growth outlook, brokerage clsa has said in a note. according to the brokerage, large-cap drugmakers are better positioned to ride the next wave of growth in the us owing to their superior research and development, better execution, and stronger balance sheets. clsa has cited sun pharmaceutical industries, lupin, dr reddy’s and torrent pharmaceuticals as its best ideas. sun pharma | cmp: rs 692.30the brokerage firm has maintained ‘buy’ rating on sun pharma with a target price of rs 860 per share as the drug maker is making steady progress...

hnis, retail investors hiked stake in these stocks in q3; do you hold them?

new delhi: despite a tumultuous last quarter for india inc, individual investors, including hnis and retail investors, showed interest in select banking & finance, real estate, metals, pharma and sugar stocks during the third quarter of 2016-17. karnataka bank stood among the most favourite stock of individual investors, as their holdings in the bank rose from 57.22 per cent during the quarter ended september 30, 2016 to 59.40 per cent at the end of december quarter of fy17. investors also showed interest in other banking stocks, such as south indian bank (increased stake from 35.42 per cent to 36.05 per cent), rbl bank (from 24.75 per cent to 33.66 per cent), dcb bank (from 27.77 per cent to 29.14 per cent) and federal bank (22.44 per cent to 23.57 per cent). jammu & kashmir bank, andhra

aurobindo pharma: goldman sachs sees 40% upside in this multibagger pharma stock

new delhi: shares of aurobindo pharma were trading higher in early trade on friday after global brokerage goldman sachs maintained a ‘buy’ rating on it with a target price of rs 934, indicating a 40 per cent upside from the current level. the scrip was trading 0.65 per cent higher at rs 662.55 around 9.30 am (ist). shares of the company opened at rs 665.70 and touched a high and low of rs 666.60 and rs 660.50, respectively, in trade so far. benchmark bse sensex was up 76.57 points, or 0.26 per cent, at 29,005. goldman sachs believes new product launches in the us are gaining momentum, leading to a 14 per cent top line growth for aurobindo pharma. it further forecast a 19 per cent ebitda growth over the next two years versus 12 per cent for peers. “aurobindo pharma is transforming fro...

etmarkets after hours: 60 stocks hit 52-week highs; glenmark tanks

equity benchmarks bse sensex and nse nifty snapped a four-day gaining streak on friday as market participants preferred to book profit at higher levels. after scaling new closing highs on thursday, the 30-share sensex shed 62 points, or 0.21 per cent, to close at 30,188 on friday, while the 50-share nse nifty index slipped 21 points, or 0.23 per cent, to 9,400. here’s a look at the stocks and sectors that hogged limelight on friday:biggest intraday fall: shares of glenmark pharmaceuticals plunged over 16 per cent on friday and registered their biggest fall in seven years. the scrip plunged after the company reported lower-than-expected financial numbers for the quarter ended march 31, 2017. the pharma company on thursday reported a 23.5 per cent rise in consolidated net profit for march ..

if trump falls, stocks would rebound under pence

if president is forced out or resigns, stocks would likely bounce back after initial fall.         

etmarkets after hours: videocon, boi tumble; 35 stocks @52-wk highs

equity benchmarks bse sensex and nse nifty settled a choppy session in the green on monday following positive global cues. the 30-share bse sensex closed 106 points, or 0.35 per cent, higher at 30,570, while the nifty index settled 10.35 points, or 0.11 per cent, up at 9,438. select buying in index heavyweights such as itc, larsen & toubro, adani ports, tata motors, hindustan unilever and hdfc bank further supported the domestic market. here’s a look at the stocks and sectors that hogged limelight on monday: @fresh 52-week high: more than 35 stocks hit their fresh 52-week high on nse in monday’s trade. the list included bliss gvs pharma, caplin point, eih ltd, hdfc bank, hindustan unilever, itc, larsen & toubro infotech, mirza international and suzlon energy. earnings hurt: shares of b...

markets: bulls slowly losing the heat in market as mercury rises

the domestic equity market opened the week with positive sentiments backed by all-round optimism. media headlines also added fire power to the bulls, but somehow mr market was in no mood to respect them. the headlines read as “stocks at peak..., market at new high.., ready steady soar.., sip inflows at rs 4200 crore an all-time high..” these are the kind of headlines and sentiments needed to make intermediate tops in a large secular bull market. surprisingly this time, instead of the nifty50, there is an all-time high open interest in bank nifty, which certainly sends out a cautious signal for the bulls. some sectors that are heading at a diametrically opposite direction are pharma and it. pharma, in particular, saw massive selloff during the week, what is in store for them would be kn...

stocks: restructure portfolio, prune down those high beta midcap names: sandeep

let us talk about the current positioning. if you expect the index to fall by 5% to 8%, what will happen to midcap stocks? midcap is where the froth is. there are midcap stocks which are way above the mark. these are trading way above the intrinsic values. could we have a situation of a 15% to 20% decline in midcap stocks and could it be even higher in metals, real estate, all the beta group which has gone up by 40-50% recently?i agree with that because when we say that prune down high beta names because these stocks have outperformed significantly and when risk off environment comes, it is correct. even i am more worried about base metal prices also because we have a view that base metal prices, commodities market will also correct and i will not use the word consolidate, definitely you c

pot stocks rocket higher on federal government announcement

shares in australia's fledgling crop of pot stocks rocketed higher on wednesday, following an announcement by the federal government aiming to boost cannabis supply and relax importation laws.the announcement comes just one week after the first licence for private cultivation was issued to privately owned cann group, allowing them to cultivate marijuana in australia. boris trajkov has been charged with cultivating a commercial quantity of cannabis. photo: suppliedinvestors flooded into listed marijuana plays. creso pharma shares had spiked 8 per cent at lunch time, mmj phytotech was up 9 per cent, mgc pharmaceuticals was up 8 per cent and auscann had soared 24 per cent.federal health minister greg hunt said the changes would ensure there was enough supply for "all of the medical dem...

pharma firms unhappy with my decision to reduce cost of stents, medicines: pm mo

by: express web desk | new delhi | updated: april 17, 2017 11:36 am prime minister narendra modiprime minister narendra modi on monday said certain pharma companies were upset about his government’s decision to reduce the price of stents and certain medication. he was speaking after inaugurating the kiran multispeciality hospital in surat, gujarat.“many pharma firms are unhappy with my decision of cheaper stents, medicines,” he said, adding that the focus now has to been on preventive healthcare and the swachh bharat abhiyan is a step towards that. “after assuming office, mechanisms were put to bring down prices of medicines even if that meant pharma companies are unhappy with us. there are powerful people who are unhappy with me. but, my commitment is to provide affordable he...

chasing new highs: strong liquidity to fuel further gains in select stocks

nifty crossed the 9,000-level on monday after almost two years. during this period, over 1,000 stocks outperformed the broader indices with some large caps like bajaj finserve, bajaj finance, hpcl, petronet lng, piramal enterprises and india oil doubling, while mid-cap stocks like jubilant life, chennai petroleum and aegis logistics, among others, fetched 400% returns. after the rally, many of them are at record highs, mirroring the nifty levels, yet analysts are betting on more action in these stocks, thanks to the unabated liquidity flows.

there's no need to choose between quality and value stocks on asx: morgan stanle

taking a stake in australia's best companies usually requires investors to pay a hefty premium. but that's not the case at the moment, with many of australia's premier corporates going for cheap, according to the quants at morgan stanley. the high valuations of quality stocks normally forces investors into a trade-off between quality and value investing styles – either they buy the best, companies with solid business models and balance sheets, or those posing good value, that is, those selling for cheap relative to their earnings.  the rising sharemarket has boosted junk stocks over quality stocks, but the difference between the two is small. photo: tamara voninskibut on the asx, the valuation premium for quality stocks is below its five-year average, so top businesses such ...

stocks: expect double digit growth in consumer goods sector: andrew holland, ave

in a chat with et now, andrew holland, ceo, avendus capital alternate strategies, says for the first time in many years, sees growth coming back to the consumer goods sector. there will be a shift away from it and pharma towards this sector going forward. edited excerpts: how you are positioned in this market that is showing no signs of caving in under any pressure? right now how is your fund placed given the abundance of liquidity?momentum is still there. it is too difficult to be bearish at the moment in terms of saying that we expect markets to fall. we do expect markets to fall but the catalyst which we thought might be there seemed to be evaporating. lke france could be a trigger but that has obviously cooled down since macron took the lead. but that said, valuations are very high. th

midcaps & smallcaps lead fall, china adds to fears

mumbai: mid-cap shares continued to suffer on wednesday as videocon industries, bank of india, and stocks belonging to the anil ambani group posted sharp declines amidst weak overall market sentiment caused by the downgrade of china. investors unwound excessively leveraged positions in the f&o segment and punished stocks with weak financials and high debt. of the 950 bse-listed stocks with market capitalicaiton more than rs 500 crore, 80 declined 15%-42% in five days while another 200 stocks fell between 10% and 15% during the period. another 400 companies fell between 5% and 10%. indian stock indices ended on a subdued note on wednesday weighed down by moody's decision to downgrade china for the first time in 30 years. the sensex ended at 30,301.64, down 63.61 points or 0.2% while the ni.

fun, alternative facts about your 6 favorite cities! from clara morris

philadelphiaresidents have more blood than the rest of usrich with history, philadelphia is the location of the first boston tea party. scones were served and madam billingsworth spilled on her petticoat, embarr ing her family to this day.home of sack the cownew york citypart of atlantisfounded by christopher columbus’ younger brother huey columbus. huey actually found nyc by accident, while chasing a erfly that ended up just being a regular fly.was originally named york city ii: you ain’t seen nothin’ yethoustona city on the cutting edge of technology with a robot mayor and metal treesbirthplace of supermanhouston was made famous in 1941, when cupid’s arrow pierced the throat of a local resident, killing him in front of his soulmate.chicagofloats in saltwaterkentucky derby winning horse s